Medivir AB (publ) (STO:MVIR)
Sweden · Delayed Price · Currency is SEK | Market Cap | 1.22B +458.8% |
| Revenue (ttm) | 8.71M +118.5% |
| Net Income | -87.30M |
| EPS | -0.26 |
| Shares Out | 617.94M |
| PE Ratio | n/a |
| Forward PE | 38.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 903,856 |
| Open | 1.922 |
| Previous Close | 1.978 |
| Day's Range | 1.920 - 1.978 |
| 52-Week Range | 0.340 - 2.885 |
| Beta | 0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About Medivir AB
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of medical treatments in areas of high unmet medical need in Sweden, the Nordic region, the rest of Europe, and internationally. The company offers Xerclear (Zoviduo), a combination of a polymerase inhibitor and hydrocortisone for the treatment of labial herpes; and Olysio (simeprevir), a protease inhibitor for the treatment of hepatitis C. It also develops remetinostat, a histone deacetylase (HDAC) inhibitor that is in a Phase II trial for the treatme... [Read more]
Financial Performance
In 2025, Medivir AB's revenue was 8.51 million, an increase of 144.14% compared to the previous year's 3.48 million. Losses were -94.40 million, -23.45% less than in 2024.
Financial StatementsNews
Medivir AB Earnings Call Transcript: Q2 2026
Fostrox plus lenvatinib showed strong efficacy and safety in HCC, with phase II FLEX-HCC study recruitment on track. MIV-711 advanced into two rare bone indications, both fully funded, and cash reserves now cover all phase II studies into 2030.
Medivir AB Quarterly report: Q2 2026
Medivir AB has published its Q2 2026 quarterly earnings report on August 20, 2026.
Medivir AB Slides: Q2 2026
Medivir AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Medivir AB Slides: Company presentation
Medivir AB has posted slides in relation to its latest quarterly earnings report, which was published on July 3, 2026.
Medivir AB Earnings Call Transcript: Q1 2026
Q1 2026 saw strengthened finances, high engagement in the FLEX-HCC liver cancer study in Korea, and progress in rare disease and veterinary programs. Operating loss improved, cash position remained strong, and key clinical milestones are on track for 2026–2027.
Medivir AB Quarterly report: Q1 2026
Medivir AB has published its Q1 2026 quarterly earnings report on May 5, 2026.
Medivir AB Slides: Q1 2026
Medivir AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Medivir AB Slides: FY 2026
Medivir AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 9, 2026.
Medivir AB Earnings Call Transcript: Q4 2025
Strong pipeline progress with MIV-711 advancing into phase II for OI after new funding and FDA orphan drug status, Fostrox liver cancer study on track, and partnered VBX-1000 showing promising animal health results. Cash runway extends into 2028.
Medivir AB Annual report: Q4 2025
Medivir AB has published its Q4 2025 annual report on February 18, 2026.
Medivir AB Quarterly report: Q4 2025
Medivir AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
Medivir AB Slides: Q4 2025
Medivir AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 18, 2026.
Medivir AB Slides: Company presentation
Medivir AB has posted slides in relation to its latest quarterly earnings report, which was published on January 22, 2026.
Medivir AB Slides: Company presentation
Medivir AB has posted slides in relation to its latest quarterly earnings report, which was published on November 28, 2025.
Medivir AB Slides: FY 2025
Medivir AB has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 27, 2025.
Medivir AB Slides: FY 2025
Medivir AB has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 25, 2025.
Medivir AB Slides: Investor presentation
Medivir AB has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2025.
Medivir AB Transcript: Life Science Summit 2025
A novel liver-targeted therapy for advanced liver cancer is advancing to a phase II trial, aiming to fill a major gap in second-line treatment. Early results show strong tumor response and extended progression times, with a $2.5–3 billion market opportunity.
Medivir AB Earnings Call Transcript: Q3 2025
Announced a fully guaranteed rights issue to fund a phase II study of fostrox + Lenvima in second-line liver cancer, with rapid data generation targeted. Outlicensed Remetinostat to Biossil, securing milestone and royalty potential. Q3 financials showed improved operating loss and cash flow.
Medivir AB Quarterly report: Q3 2025
Medivir AB has published its Q3 2025 quarterly earnings report on November 6, 2025.
Medivir AB Slides: Q3 2025
Medivir AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 6, 2025.